Literature DB >> 16982183

Antifungal treatment in sarcoidosis--a pilot intervention trial.

Marjeta Tercelj1, Tomaz Rott, Ragnar Rylander.   

Abstract

BACKGROUND: Sarcoidosis is generally treated with corticosteroids that are not always an effective therapy.
OBJECTIVES: To assess if treatment with antifungal drugs would improve the clinical status of patients with sarcoidosis.
METHODS: Patients (n=18) with sarcoidosis grades II and III according to established criteria and without clinical and immunological signs of fungal infection, were treated with antifungal medication together with corticosteroids for 3-6 months. Pulmonary X-ray infiltration, lung function, and severity of symptoms were registered before and after the treatment and at follow up 9-58 months later.
RESULTS: The treatment resulted in statistically significant decreases in the degree of pulmonary infiltration with an average decrease in the group from 2.0 to 1.0. There were also significant increases in diffusion capacity and decreases in the severity of symptoms.
CONCLUSION: It is suggested that treatment with antifungal drugs may be useful, at least in certain cases of sarcoidosis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16982183     DOI: 10.1016/j.rmed.2006.08.005

Source DB:  PubMed          Journal:  Respir Med        ISSN: 0954-6111            Impact factor:   3.415


  9 in total

1.  Role of chitotriosidase (chitinase 1) under normal and disease conditions.

Authors:  Manasa Kanneganti; Alan Kamba; Emiko Mizoguchi
Journal:  J Epithel Biol Pharmacol       Date:  2012

2.  In vitro and in vivo reactivity to fungal cell wall agents in sarcoidosis.

Authors:  M Terčelj; S Stopinšek; A Ihan; B Salobir; S Simčič; B Wraber; R Rylander
Journal:  Clin Exp Immunol       Date:  2011-10       Impact factor: 4.330

3.  Human chitotriosidase: a sensitive biomarker of sarcoidosis.

Authors:  Elena Bargagli; David Bennett; Claudia Maggiorelli; Pasquale Di Sipio; Maria Margollicci; Nicola Bianchi; Paola Rottoli
Journal:  J Clin Immunol       Date:  2012-08-10       Impact factor: 8.317

4.  CD4+ T cells in the lungs of acute sarcoidosis patients recognize an Aspergillus nidulans epitope.

Authors:  Johan Grunewald; Andrew P Fontenot; Sarah A Greaves; Avinash Ravindran; Radleigh G Santos; Lan Chen; Michael T Falta; Yang Wang; Angela M Mitchell; Shaikh M Atif; Douglas G Mack; Alex N Tinega; Lisa A Maier; Shaodong Dai; Clemencia Pinilla
Journal:  J Exp Med       Date:  2021-08-19       Impact factor: 17.579

Review 5.  Unconventional uses of common conventional drugs: A review.

Authors:  Anupam Das; Abheek Sil; Shouvik Ghosh; Saumya Panda
Journal:  Indian J Dermatol Venereol Leprol       Date:  2021 Jul-Aug       Impact factor: 2.545

6.  Cardiac sarcoidosis: a comprehensive review.

Authors:  Vishal Sekhri; Shireen Sanal; Lawrence J Delorenzo; Wilbert S Aronow; George P Maguire
Journal:  Arch Med Sci       Date:  2011-09-02       Impact factor: 3.318

Review 7.  Interleukin-12 family cytokines and sarcoidosis.

Authors:  Sabine Ringkowski; Paul S Thomas; Cristan Herbert
Journal:  Front Pharmacol       Date:  2014-10-27       Impact factor: 5.810

8.  Sarcoidosis treatment with antifungal medication: a follow-up.

Authors:  Marjeta Terčelj; Barbara Salobir; Mirjana Zupancic; Ragnar Rylander
Journal:  Pulm Med       Date:  2014-12-04

9.  Fungal cell wall agents and bacterial lipopolysaccharide in organic dust as possible risk factors for pulmonary sarcoidosis.

Authors:  Sanja Stopinšek; Alojz Ihan; Barbara Salobir; Marjeta Terčelj; Saša Simčič
Journal:  J Occup Med Toxicol       Date:  2016-09-21       Impact factor: 2.646

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.